Core Viewpoint - Bank of America Securities has raised its revenue forecasts for WuXi Biologics (02269) for 2025 to 2027 by 1%, 5%, and 8% respectively, and increased the target price from HKD 35 to HKD 41.8 to reflect the company's rapid development in R&D and production stages, as well as the high growth visibility of its CMO business [1] Group 1 - WuXi Biologics added 209 integrated projects last year, representing a year-on-year increase of 38%, with two-thirds being complex models (bispecific and multispecific antibodies and antibody-drug conjugates), and approximately half coming from U.S. clients [1] - The company secured 23 new projects last year, including 6 late-stage projects, with about half originating from U.S. clients and over 50% being complex models [1] - As of the fiscal year 2025, WuXi Biologics holds a total of 945 projects, which include 463 in preclinical stage, 289 in Phase I, 94 in Phase II, 74 in Phase III, and 25 in commercialization stage [1]

药明生物去年新增209个综合项目，同比增加38%，当中三分之二属复合模式(双特异性及多特异性抗体 以及抗体药物偶联物)，约半数来自美国客户。此外，公司去年亦获得23个项目，包括6个后期阶段项 目，其中约半数来自美国客户，超过50%属复合模式。截至2025财年，公司持有945个项目，包括临床 前阶段463个、一期临床289个、二期临床94个、三期临床74个及商业化阶段25个项目。 智通财经APP获悉，美银证券发布研报称，为反映去年药明生物(02269)于研发及生产阶段的快速发展， 并考虑到其CMO业务具高增长能见度，该行将2025至2027年收入预测分别上调1%、5%及8%，目标价 由35港元上调至41.8港元。 ...

大和指，药明生物去年净新增项目128个，多于该行预测的105个。期内毛新增209个项目，半数来自美 国客户，三分二为双特异性/多特异性抗体及ADC。去年新签合约潜在里程碑总额最高可达40亿美元。 公司去年完成28个PPQ，今年则已有34个排期。 大和发布研报称，上调对药明生物(02269)目标价，由35.5港元上调至42港元，维持"买入"评级。该行上 调对药明生物2025年至2027年每股盈利预测1%至5%，基于新签项目预期上升及持续的经营开支杠杆， 以及上调2028至2032年收入预测3%至7%，基于项目增长趋势上调。 ...

大和指，药明生物去年净新增项目128个，多于该行预测的105个。期内毛新增209个项目，半数来自美 国客户，三分二为双特异性/多特异性抗体及ADC。去年新签合约潜在里程碑总额最高可达40亿美元。 公司去年完成28个PPQ，今年则已有34个排期。 智通财经APP获悉，大和发布研报称，上调对药明生物(02269)目标价，由35.5港元上调至42港元，维 持"买入"评级。该行上调对药明生物2025年至2027年每股盈利预测1%至5%，基于新签项目预期上升及 持续的经营开支杠杆，以及上调2028至2032年收入预测3%至7%，基于项目增长趋势上调。 ...

Group 1 - The core viewpoint of the news highlights the rapid growth of Qianwen's C-end monthly active users (MAU), which has surpassed 100 million within two months, particularly among students and white-collar workers [1] - China Galaxy Securities emphasizes the continuous catalysis of the AI industry, indicating that the commercialization of AI applications has vast development potential, with generative search (GEO) as a key area of exploration [1] - The report suggests that AI is not only reducing costs and increasing efficiency but also enhancing user interaction experiences, particularly in gaming and content sectors, thereby significantly improving user engagement [1] Group 2 - As of January 14, 2026, the CSI Hong Kong Stock Connect Technology Index (931573) has risen by 1.62%, with notable increases in constituent stocks such as Alibaba Health (up 14.07%), Qutoutiao (up 11.53%), and Jiufang Zhitu Holdings (up 7.78%) [1] - The CSI Hong Kong Stock Connect Technology Index comprises 50 large-cap, high R&D investment, and high revenue growth technology leading companies, reflecting the overall performance of technology leaders within the Hong Kong Stock Connect [2] - The top ten weighted stocks in the CSI Hong Kong Stock Connect Technology Index, as of December 31, 2025, include Meituan-W, Tencent Holdings, Alibaba-W, and Xiaomi Group-W, collectively accounting for 69.68% of the index [2]

Core Viewpoint - The stock of CSPC Pharmaceutical Group (01093) has shown significant movement, with a 53% increase in related warrants, indicating strong market interest and potential for further price challenges in the near future [1][7]. Company Analysis - CSPC Pharmaceutical's latest stock price is 9.96 HKD, with a slight increase of 1.53% and a trading volume of 6.79 billion HKD. The current support levels are at 8.90 HKD and 8.18 HKD, while resistance levels are at 10.32 HKD and 11.00 HKD, suggesting a 51% probability of upward movement [1]. - The technical indicators for CSPC show an RSI of 76, indicating an overbought condition, and both the Williams and stochastic indicators are signaling a sell [2]. - The stock has rebounded to 10 HKD after a previous high of 11.49 HKD in August-September of the previous year, suggesting potential for future price challenges [4]. Industry Insights - The application of AI in the biopharmaceutical sector is highlighted as a key driver for innovation and profitability, with CSPC and similar companies benefiting from this trend [4]. - The biopharmaceutical sector, including companies like WuXi Biologics (2269), is experiencing high market expectations for profitability, with stock prices reflecting this optimism [5][6]. - The overall sentiment in the biopharmaceutical sector is strong, but technical indicators suggest that many stocks, including CSPC, are facing overbought conditions, indicating a potential for price corrections [6][7]. Warrants and Leverage - The warrants related to CSPC have shown significant leverage effects, with some warrants increasing by as much as 53% in response to the stock's movements. The warrants' performance indicates a strong correlation with the underlying stock [7][9]. - Specific warrants, such as the HSBC call warrant (17233), have a leverage of 7.5 times and are positioned close to the current stock price, enhancing their potential for value appreciation [9][10]. - The recommended warrants for cautious investors include the HSBC call warrant (17233) and the Bank of China bull warrant (65938), both of which offer favorable leverage and lower premium levels [9][11].

Market Overview - Global markets showed mixed performance, with the Hang Seng Index rising by 0.90% and the Shanghai Composite Index declining by 0.64% [1][3] - The US stock market experienced slight declines, with the Dow Jones down by 0.80% and the S&P 500 down by 0.19% [1][3] - Japanese stocks reached new highs, supported by expectations of continued expansionary fiscal policies [3] Hong Kong Stock Performance - The Hang Seng Financial Index increased by 1.36%, while the Hang Seng Real Estate Index rose by 0.42% [2] - The Hang Seng Commercial Index saw a 0.70% increase, indicating positive sentiment in the commercial sector [2] Chinese Stock Market Insights - The Chinese stock market exhibited mixed results, with sectors such as defense and electronics facing declines, while oil and pharmaceuticals showed gains [3] - Southbound capital saw a net inflow of HKD 1.296 billion, with notable purchases in Alibaba, Tencent, and Xiaomi [3] Company Analysis: JD.com - JD.com is projected to achieve total revenue of RMB 349.2 billion in Q4 2025, reflecting a year-on-year growth of 0.6% [5] - Non-GAAP net profit is expected to drop significantly by 96% to RMB 484 million, primarily due to increased investment in the delivery business and high base effects from the previous year [5] - The target price for JD.com has been adjusted to USD 46.8, reflecting a downward revision in profit forecasts [5] Company Analysis: China Resources Mixc Lifestyle - China Resources Mixc Lifestyle is expected to see a revenue increase of 6.5% to RMB 18.2 billion for FY25, with core net profit projected to grow by 10.8% to RMB 3.9 billion [6] - The commercial segment is anticipated to grow by 13.8%, while the residential segment remains stable [6] - The target price has been raised to HKD 53.96, reflecting a 9% increase in valuation multiples due to reduced reliance on residential business [6][7] Shopping Center Sector Insights - The shopping center sector is expected to see retail sales growth of 20-25% in FY25, driven by new consumer trends [7] - The segment's revenue is projected to grow by 18%, influenced by high base effects from the previous year [7] Residential Sector Insights - The residential sector is expected to maintain stable revenue growth of 1.3%, with property management services showing resilience [8] - The company is likely to maintain a 100% dividend payout ratio, reflecting a commitment to shareholder returns [8]

为反映去年公司于研发及生产阶段的快速发展，并考虑到其CMO业务具高增长能见度，该行将2025至 2027年收入预测分别上调1%、5%及8%，目标价由35港元上调至41.8港元，重申"中性"评级，因考虑到 公司业务发展符合预期且领先地位巩固，但同时受《生物安全法案》潜在地缘政治风险所抵消。 美银证券发表研究报告指，药明生物去年新增209个综合项目，按年增加38%，当中三分之二属复合模 式(双特异性及多特异性抗体以及抗体药物偶联物)，约半数来自美国客户。截至2025财年，公司持有 945个项目，包括临床前阶段463个、一期临床289个、二期临床94个、三期临床74个及商业化阶段25个 项目。 ...

Core Viewpoint - UBS reaffirms a "Buy" rating for WuXi AppTec's subsidiary WuXi Biologics, setting a target price of HKD 89.5, based on its leading position in the bioconjugate CRDMO platform, ongoing capacity expansion, and manageable geopolitical risks [1] Group 1: Company Performance - WuXi Biologics is expected to add over 70 projects from WuXi AppTec in 2025, significantly higher than the previous guidance of over 60 projects [1] - The company anticipates a compound annual growth rate (CAGR) of approximately 30% in revenue over the next five years, outpacing the industry average [1] Group 2: Market Environment - The impact of the U.S. Biodefense Act is being actively addressed by WuXi Biologics through communication with clients and the U.S. government, with a low likelihood of being included in the related list [1] - Concerns from clients are currently limited, and the expansion of in-house capacity by multinational pharmaceutical companies in the bioconjugate field remains constrained, suggesting a sustained high outsourcing ratio [1] Group 3: Future Outlook - With a strong business track record, WuXi AppTec is well-positioned to continue securing new orders globally, including in North America [1]

1. Report's Investment Rating for the Industry - No information provided regarding the report's investment rating for the industry 2. Core Viewpoints of the Report - On January 13th, all four major index futures contracts for the current month declined, with IF down 0.56%, IH down 0.21%, IC down 1.26%, and IM down 1.92%. The total trading volume of index futures rebounded on this trading day, indicating increased trading enthusiasm among investors, while the total open interest of IF, IH, and IC increased, and that of IM decreased. The Shanghai Composite Index ended its 17 - day winning streak, the ChiNext Index fell nearly 2%, and the Hong Kong stock market oscillated upwards with pharmaceutical stocks leading the gains [1][2][7] 3. Summary by Relevant Catalogs 3.1 Index Futures Data Tracking - **Index Futures Closing Prices and Changes**: On January 13th, the closing price of the CSI 300 was 4761, down 0.60%; the closing price of the SSE 50 was 3132.9, down 0.34%; the closing price of the CSI 500 was 8143.3, down 1.28%; the closing price of the CSI 1000 was 8203.1, down 1.84%. Among the corresponding index futures contracts, the prices of all current - month contracts declined, with the decline of IM being the largest [1] - **Index Futures Trading Volume and Open Interest Changes**: The total trading volume of IF increased by 16,637 lots, IH by 13,333 lots, IC by 8960 lots, and IM by 6539 lots. The total open interest of IF increased by 5440 lots, IH by 3136 lots, IC by 6136 lots, and IM decreased by 1419 lots [2] - **Index Futures Basis**: The basis of different contracts varies, such as IF2601 with a basis of 5.17, IH2601 with 3.67, IC2601 with 29.52, and IM2601 with 30.67 [1] 3.2 Index Futures Top 20 Member Open Interest Changes - Different contracts of IF, IH, IC, and IM have different changes in long and short positions. For example, in IF2601, long positions decreased by 3789 and short positions decreased by 3971; in IH2603, long positions increased by 1875 and short positions increased by 1134 [5] 3.3 Trend Intensity - The trend intensity of IF and IH is 1, and that of IC and IM is also 1, indicating a neutral trend [6] 3.4 Important Drivers - The Ministry of Industry and Information Technology issued the "Action Plan for Promoting the High - Quality Development of Industrial Internet Platforms (2026 - 2028)", aiming to achieve positive results in the high - quality development of industrial internet platforms by 2028. The ministry also held the 18th manufacturing enterprise symposium, emphasizing industry self - discipline and a win - win situation [6][7] 3.5 A - share Market Closing Summary - The Shanghai Composite Index fell 0.64% to close at 4138.76 points, the Shenzhen Component Index fell 1.37%, the ChiNext Index fell 1.96%, and the A - share market turnover reached 3.7 trillion yuan, setting a new record. Innovative drug concept stocks strengthened, while commercial aerospace concept stocks adjusted significantly [7] 3.6 Hong Kong Stock Market Closing Summary - The Hang Seng Index rose 0.9% to close at 26,848.47 points, the Hang Seng Tech Index rose slightly by 0.11% to 5869.79 points, and the Hang Seng China Enterprises Index rose 0.71% to 9285.41 points. The market turnover was HK$315.192 billion, an increase from the previous trading day [8]